Triggers for a Monitoring or Audit Visit
The NBT policy is to monitor 100% of all ctIMPs and Device investigations for which NBT is the sponsor, at least annually.
If your study is sponsored by a commercial company then you must expect more regular monitoring and allow time for this in your work schedule.
As a host organisation, NBT aims to monitor 25% of ctIMPs and Device Investigations for which NBT is not the Sponsor. In addition, NBT will monitor any NBT sponsored project which reports a Suspected Unexpected Serious Adverse Reaction (SUSAR) and monitor any commercial project withdrawn prematurely for reasons, other than safety, unless recently monitored by the Sponsor.
Audit and monitoring visits may take place at any time, although adequate notice will be given. It is important that the project documentation is well-maintained and accessible at all times.
It is important to let your sponsor know once your first patient is recruited to allow for monitoring after the first participant visit. This can help to smooth a document pathway and ensure that data is collected in accordance with GCP & ICH guidelines.
Monitors/auditors will need access to participant medical records, and this must be provided by the research team. The sponsor will give you notice which participant notes they require. It is the responsibility of the entire research team to ensure that medical notes are correctly traced on CERNER.
View Our Research
Explore the ground-breaking research currently taking place at North Bristol NHS Trust.
About Research & Development
Find out more about our research and how we're working to improve patient care.
Contact Research
Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB
Telephone: 0117 4149330
Email: research@nbt.nhs.uk

“Well over 20 years ago, I lost the sight in my left eye and after initially going to my local eye hospital I was passed on to a Neurologist. After a series of tests I was diagnosed with MS. I was only 24. This was a shock as I knew someone who had the disease and she used a wheelchair. My wife and I were expecting our first child so I was worried how my MS was going to affect me and my family. My family were all very supportive and together we found out more about the disease. Although I continued to work as an engineer for another 7 years, I became more and more tired; I now know this to be fatigue.
I eventually had to stop working as an engineer and so wanted to find something to keep me occupied. Five years ago I was introduced to a team of Neurological Consultant Doctors who told me of their idea to create an MS centre of excellence in Bristol, where people could receive treatment for the disease and be involved in new drug trials under a specialist team of MS doctors, nurses and a physiotherapist. They asked if I would help them raise funds for the unit and so became their Voluntary Fundraising Manager in 2007.
Disease modifying drugs are not a cure for MS, but they can reduce the frequency and severity of relapses. If you experience relapses these drugs may help, but they are not effective for primary progressive MS.
Relapsing remitting MS is the most common type of MS, affecting around 85 per cent of those diagnosed. It means that symptoms appear (a relapse), and then fade away, either partially or completely.
It is not uncommon for a diagnosis to take several months, and frustratingly it can take even longer. A range of other possible causes need to be explored and many different tests need to be carried out.

